Boston Scientific (NYSE:BSX) CEO Mike Mahoney has been named as Glassdoor.com’s Employee’s Choice number two top CEO of 2018, falling just behind Zoom Video Communications’ Eric Yuan. Mahoney was the only medtech exec to make the top 10 list, while Johnson & Johnson‘s (NYSE:JNJ) Alex Gorsky came in at 28 and Stryker’s Kevin Lobo at 100. […]
Dr. Gawande tapped to lead Amazon-JPM-Berkshire health play | Personnel Moves – June 21, 2018
The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate […]
Boston Scientific wins third Mass. pelvic mesh trial
Boston Scientific (NYSE:BSX) last week won the third Massachusetts trial of a product liability lawsuit brought over two of its pelvic mesh products. Ana Martinez and her husband Jose sued Marlborough, Mass.-based Boston Scientific in August 2012 in the Bay State’s Middlesex County Superior Court. After a 16-day trial, the jury found June 15 that Boston was […]
Stryker dismisses Boston Scientific buyout rumors, sees shares rebound
Stryker (NYSE:SYK) today put the rumors that it was interested in a takeover of Boston Scientific (NYSE:BSX) to rest and has seen shares rise in response. Rumors emerged of a possible takeover bid from the Kalamazoo, Mich.-based company emerged on Monday in a Wall Street Journal report, after which both companies officially responded with statements of “no […]
Analysts: Stryker, Boston Scientific tie-up could create “higher growth Medtronic”
Analysts are eagerly digging into the news that Stryker (NYSE:SYK) put in a takeover bid with Boston Scientific (NYSE:BSX), though many were surprised by the news and are unsure of the obvious strategic value of the acquisition. News of the deal, which both companies have officially responded to with statemens of “no comment,” emerged yesterday at the […]
Report: Stryker puts in takeover bid for Boston Scientific
Stryker (NYSE:SYK) has put in a bid as it looks to acquire rival Boston Scientific (NYSE:BSX), according to a new report from the Wall Street Journal. Boston Scientific has not actively responded to the approach, according to the report, which came from sources “familiar with the matter,” according to the WSJ. “As a matter of company policy, […]
Boston Scientific, IRS finalize $608m settlement over transfer pricing beef
Boston Scientific (NYSE:BSX) and the U.S. Internal Revenue Service yesterday finalized their settlement of a tax beef dating back to the $26 billion acquisition of Guidant in 2006, which would see the company pay nearly $610 million in taxes and interest. In transfer pricing, income is allocated among branches in different countries. It’s a legal tax maneuver companies can […]
EuroPCR Roundup: Biotronik touts two-year study comparing drug-eluting stents
Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent. Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of […]
EuroPCR 2018: Study compares drug-coated balloons in patients with arterial in-stent restenosis
At this year’s annual EuroPCR meeting, Boston Scientific (NYSE:BSXtouted results from the first trial to compare two drug-coated balloons with different drug formulations – Boston Scientific’s Agent paclitaxel-coated PTCA device and B. Braun’s SeQuent Please balloon. The 125-patient study evaluated the balloons in patients with in-stent restenosis of a lesion previously treated with a drug-eluting stent or drug-coated balloon. […]
8 companies commercializing transcatheter mitral valve replacements
Transcatheter mitral valve replacement is a new frontier in the cardio device field, with big legacy medical device companies including Edwards Lifesciences, Medtronic and Abbott spending hundreds of millions of dollars on companies in the space. Much different from transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) has been mostly experimental. TMVR is used […]
Boston Scientific touts safety, effectiveness in Rhythmia mapping study
Boston Scientific‘s (NYSE:BSX) Rhythmia mapping system and catheter was found to be safe and effective in procedures to treat arrhythmias, according to a Healio summary of a newly released study from the company. Researchers in the study examined 572 patients, with 519 patients undergoing procedures with the Rhythmia system and IntellaMap Orion catheter, according to […]
- 1
- 2
- 3
- …
- 130
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+